Managing Pulmonary Oligometastatic Disease With Stereotactic Body Radiation Therapy-Moving the Field Forward 1 Organ at a Time

Affiliations

Comment

Arya Amini. JAMA Oncol. 2021.

. 2021 Oct 1;7(10):1485-1486.

doi: 10.1001/jamaoncol.2021.2926.

¹ Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California.

No abstract available

Comment on

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Siva S, et al. JAMA Oncol. 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. JAMA Oncol. 2021. PMID: 34455431 Free PMC article. Clinical Trial.